Infanrix-IPV

Packaging changes Synflorix® & Infanrix®-IPV

Wednesday, 31 October 2012

The packaging for Synflorix® and Infanrix®-IPV is changing. The vaccine formulations have not changed.

The new Synflorix® packs have been designed to reduce the risk of breakage, be more secure (tamper-evident) and environmentally friendly. Lettering on the Synflorix® syringe has changed from green to black so it is easier to read. The new packaging is expected to arrive at practices from December 2012. A GSK letter about Synflorix® packaging changes will be mailed to all practices and will also go out with ProPharma orders during the first month the new packs are distributed.

The new Infanrix®-IPV packs have been designed to be more secure (tamper-evident), smaller in size and environmentally friendly. The new packaging is expected to begin arriving at practices from early to mid-May 2013.

Show in archive
Archived: 
0
Archive Date: 

Infanrix®-IPV

DTaP-IPV

Infanrix®-IPV is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis and poliomyelitis. Infanrix®-IPV can also be used for catch-up immunisation for children up to their 10th birthday.

What is the difference between Infanrix®-hexa, Infanrix®-IPV and Boostrix® vaccines?

Answer: 

The infant vaccine Infanrix®-hexa (DTaP-IPV-HepB/Hib) protects against six diseases (diphtheria, tetanus, whooping cough, polio, hepatitis B and Haemophilus influenzae type b (Hib) disease), while Infanrix®-IPV (DTaP-IPV) protects against the first four of these diseases. The adolescent and adult vaccine Boostrix® (Tdap) boosts protection against diphtheria, tetanus and acellular pertussis (whooping cough) but is sometimes used in a primary vaccine course.

The infant and adult vaccines contain different volumes of some active ingredients, or antigens. Infanrix®-hexa and Infanrix®-IPV have a higher volume of tetanus, diphtheria and acellular pertussis antigens, which are needed to stimulate a strong immune response. Boostrix® contains smaller doses of tetanus, diphtheria and pertussis antigens, the immune response to these invaders already exists, so the vaccine is only required to "remind" the immune response about how to respond. Local site reactions to the tetanus, diphtheria and acellular pertussis vaccines increase after the fourth dose, so the smaller dose of these components also helps to avoid these reactions in adolescents.

FAQ types: 
Subscribe to RSS - Infanrix-IPV